266 related articles for article (PubMed ID: 11159955)
1. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
McShane H; Brookes R; Gilbert SC; Hill AV
Infect Immun; 2001 Feb; 69(2):681-6. PubMed ID: 11159955
[TBL] [Abstract][Full Text] [Related]
2. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis.
Young SL; Slobbe LJ; Peacey M; Gilbert SC; Buddle BM; de Lisle GW; Buchan GS
Immunol Cell Biol; 2010 Aug; 88(6):651-7. PubMed ID: 20231853
[TBL] [Abstract][Full Text] [Related]
5. Heterologous Boost Following
Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
Front Immunol; 2018; 9():2439. PubMed ID: 30425711
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
[TBL] [Abstract][Full Text] [Related]
7. Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.
Kang H; Yuan Q; Ma H; Hu ZD; Han DP; Wu K; Lowrie DB; Fan XY
Immunology; 2014 Dec; 143(4):661-9. PubMed ID: 24965530
[TBL] [Abstract][Full Text] [Related]
8. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
9. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.
Triccas JA; Shklovskaya E; Spratt J; Ryan AA; Palendira U; Fazekas de St Groth B; Britton WJ
Infect Immun; 2007 Nov; 75(11):5368-75. PubMed ID: 17724075
[TBL] [Abstract][Full Text] [Related]
10. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
11. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice.
Ferraz JC; Stavropoulos E; Yang M; Coade S; Espitia C; Lowrie DB; Colston MJ; Tascon RE
Infect Immun; 2004 Dec; 72(12):6945-50. PubMed ID: 15557616
[TBL] [Abstract][Full Text] [Related]
12. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
Zhang M; Dong C; Xiong S
Hum Vaccin Immunother; 2017 Apr; 13(4):816-822. PubMed ID: 27960596
[TBL] [Abstract][Full Text] [Related]
13. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
[TBL] [Abstract][Full Text] [Related]
15. Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
Billeskov R; Christensen JP; Aagaard C; Andersen P; Dietrich J
PLoS One; 2013; 8(8):e72185. PubMed ID: 23977248
[TBL] [Abstract][Full Text] [Related]
16. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
17. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.
Tanghe A; D'Souza S; Rosseels V; Denis O; Ottenhoff TH; Dalemans W; Wheeler C; Huygen K
Infect Immun; 2001 May; 69(5):3041-7. PubMed ID: 11292722
[TBL] [Abstract][Full Text] [Related]
18. A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis.
Dey B; Jain R; Gupta UD; Katoch VM; Ramanathan VD; Tyagi AK
PLoS One; 2011; 6(8):e23360. PubMed ID: 21858087
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
Lu M; Xia ZY; Bao L
Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
[TBL] [Abstract][Full Text] [Related]
20. A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge.
Cai H; Yu DH; Hu XD; Li SX; Zhu YX
DNA Cell Biol; 2006 Aug; 25(8):438-47. PubMed ID: 16907641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
